Health

US panel recommends Pfizer COVID vaccine for younger children

Credit: Unsplash / CC0 public domain

The US government’s advisory medical committee approved the Pfizer COVID-19 vaccine for ages 5 to 11 on Tuesday, paving the way for young children to receive injections within a few weeks.

Independent experts have concluded that the known benefits outweigh the known risks not only directly to the health of the child, but also at the end of school and other turmoil.

After a day of presentation and debate, the final vote was 17 votes in favor and 1 abstention.

The Food and Drug Administration, which convened the meeting, is expected to give a formal green light soon, and by mid-November, 28 million young Americans will be targeted for shooting.

“When I hear, it’s pretty clear to me that the benefits outweigh the risks. Children Children are dying in the ICU, with long-term consequences after COVID. “

“Never know everything, the problem is when you know enough,” said Paul Offit, a pediatrician at the Children’s Hospital of Philadelphia.

He is in a position to benefit many high-risk children, and the theoretical risk of myocarditis, the most anxious side effect, is a low dose of 10 micrograms compared to 30 micrograms in the elderly. He added that it would probably be very low considering that. ..

Nonetheless, some experts have partially cave their votes, saying they do not support it widely. vaccination School obligations and shots must remain a personal decision for the family.

Earlier, FDA’s top vaccine scientist Peter Marks said Young children “It’s far from being harmed by COVID-19,” he added, adding that the group had 1.9 million infections and 8,300 hospitalizations, about one-third of which required intensive care.

He added that there were about 100 deaths, making it one of the top 10 causes of death.

Rare side effects

An analysis by Pfizer, posted by the FDA prior to the meeting, showed that the vaccine was 90.7 percent more effective in preventing symptomatic COVID-19.

FDA scientist Hong Yang presented a risk-benefit model showing that vaccines prevent hospitalization with COVID far more than the vaccine can cause from myocarditis at current infection rates.

This can change if community infections have dropped to very low levels, but vaccination may still be worthwhile because of the long-term risks associated with unhospitalized cases. No, she added.

These include Pediatric Multisystem Inflammatory Syndrome (MIS-C). This is a rare but very serious post-viral complication that affects more than 5,000 children of all ages and kills 46 people.

In its clinical trial, Pfizer evaluated safety data from a total of 3,000 vaccinated participants. The most common side effects are mild or moderate, such as injection site pain, malaise, headache, myalgia, and chills.

There were no cases of myocarditis or pericarditis (inflammation around the heart), but experts agreed that there were not enough research volunteers to detect very rare side effects.

CDC researcher Matthew Oster gave a presentation on what is previously known about these side effects among groups already eligible for vaccines.

According to official data, 829 of the 877 vaccine-induced myocardial inflammation cases under the age of 29 were hospitalized.The majority were discharged, but five Intensive care..

This rate is probably lower in the 5-11 year old group than in adolescent men, as it is thought to be related to testosterone.

The panel weighed this theoretical risk for the prevention of COVID, which can cause more frequent and severe myocarditis.

The conference will take place as the United States emerges from the latest waves driven by the Delta Variant.

Overall, 57 percent of the total population is fully vaccinated.

Vaccine confidence has risen in recent months, but the United States lags behind all other G7 countries in proportion to its fully vaccinated population.


US is considering approval of Pfizer COVID vaccine for infants


© 2021 AFP

Quote: US panel for infants obtained on October 26, 2021 from https: //medicalxpress.com/news/2021-10-panel-pfizer-covid-vaccine-younger.html (October 26, 2021) ) Recommends Pfizer COVID vaccine

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.



US panel recommends Pfizer COVID vaccine for younger children Source link US panel recommends Pfizer COVID vaccine for younger children

Related Articles

Back to top button